Pamisel Presents Research Achievements at ISSCR Conference

Pharmicell announced on the 11th that it presented three research achievements, including the efficiency and safety effects of the cell culture medium Half-Serum DMEM, at the ‘2024 International Society for Stem Cell Research (ISSCR) Annual Meeting.’

The International Society for Stem Cell Research was established in 2002 to promote stem cell research. The society has over 4,000 stem cell researchers from more than 60 countries worldwide participating. Authorities covering everything from basic stem cell research to therapeutics attend the conference.

The conference, held over four days from the 10th to the 13th in Hamburg, Germany, was attended by companies such as Novo Nordisk, Bayer, BlueRock Therapeutics, Stemcell Technologies, and stem cell researchers from Denmark, the United States, Germany, Canada, and other countries, exchanging various agendas.

Through research on the efficiency and safety of Half-Serum DMEM, Pharmicell confirmed that when using Half-Serum DMEM, proliferation rate, cell cycle, transient transfection, and lentivirus infection efficiency showed stable values, verifying the product’s reliability through research results. In addition, Pharmicell presented a total of three research achievements, including ▲a study on the mechanism of action and reactivity differences using biomarkers of the stem cell therapeutic agent (Harticelgram-AMi) ▲and a study verifying the functional enhancement of GSH (glutathione)-MSC stem cells.

Half-Serum DMEM is a cell culture medium product launched by Pharmicell in 2023. This product reduces the amount of fetal bovine serum (FBS), a cell growth supplement, by half while maintaining culturing effects, providing social and economic benefits to research institutions and companies. Pharmicell is striving for ESG management by developing Half-Serum DMEM, a product that addresses the social and environmental issues of cell culture media using fetuses of pregnant cows.

A Pharmicell representative said, “We are not only developing products but also meticulously testing their performance to build trust and increase market share in the cell culture medium sector,” adding, “In addition to culture media, we will continue researching the effects of our Harticelgram-AMi and maintain exchanges with domestic and international researchers.”